Pneumococcal 21-valent Conjugate Vaccine (Merck Sharp & Dohme)

N/A

Report date: 2026/03/13 20:02:36

Base Information

Drug NamePneumococcal 21-valent Conjugate Vaccine (Merck Sharp & Dohme)
Drug Alias NamePolyvalent pneumococcal conjugate vaccine (Merck Sharp & Dohme)pPCV (Merck Sharp & Dohme)CAPVAXIVEV-116V116
ClassificationVaccines > Development/production technology > Conjugated vaccineVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPneumonia, PneumococcalPneumococcal Infections
Global Approved IndicationsPneumonia, PneumococcalPneumococcal Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/06/17
Country/TerritoryBelgiumCanadaUnited States +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme CorpMerck Sharp & Dohme BvMerck & Co Inc +[4] 
Inactive CompaniesN/A
Active IndicationsPneumonia, PneumococcalPneumococcal Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A